Beam doses first patient with base-edited cell therapy
Beam Therapeutics announced Tuesday that it dosed its first patient with its base-edited CAR-T treatment last month.
BEAM-201 is an “off-the-shelf” cell therapy for patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) that has come back after prior treatment. Beam CEO John Evans said in a press statement that Beam’s patient was the first in the US to receive a base editing therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.